Genprex (Genprex) Institutional Ownership : 1.07% (As of Jun. 03, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genprex Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genprex's institutional ownership is 1.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genprex's Insider Ownership is 60.09%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genprex's Float Percentage Of Total Shares Outstanding is 98.59%.

Genprex Institutional Ownership Historical Data

The historical data trend for Genprex's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Institutional Ownership Chart

Genprex Historical Data

The historical data trend for Genprex can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	7.36	7.36	7.43	5.58	5.58	5.52	5.52	5.51	1.17	1.07

Genprex Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Genprex (Genprex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

2DE:Germany

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.

Executives

Catherine M Vaczy	officer: EVP & Chief Strategy Officer	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner	director, 10 percent owner, officer: Chief Executive Officer	P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar	officer: Chief Mfgr & Tech Officer	3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker	director	C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio	director	1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr.	director	1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman	officer: EVP & Chief Operating Officer	16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc.	director, 10 percent owner, officer: Chief Executive Officer	1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham	officer: Chief Operating Officer	944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth	10 percent owner	6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance	10 percent owner	8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer	officer: Chief Financial Officer	1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson	director	3001 MEANDERING RIVER COURT, AUSTIN TX 78746